Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

Where Does Liquid Biopsy Add Value in Thyroid Cancer? Biological Rationale, Technological Innovation, and Clinical

María Alonso-Chamorro¹, Ainhoa Palacios Mejorada¹, Garcilaso Riesco-Eizaguirre^1,2

¹Molecular Endocrinology Group, Faculty of Medicine, Universidad Francisco de Vitoria, 28223 Madrid, Spain.

|June 26, 2026

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity.

European thyroid journal·2025

Same author

DNA Methylation Dynamics and Prognostic Implications in Metastatic Differentiated Thyroid Cancer.

Thyroid : official journal of the American Thyroid Association·2025

Same author

Validation of dynamic risk stratification and impact of BRAF in risk assessment of thyroid cancer, a nation-wide multicenter study.

Frontiers in endocrinology·2023

Same author

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer.

Cellular and molecular life sciences : CMLS·2022

Same author

Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markers.

Clinical and translational medicine·2022

Same author

Identification of an interactome network between lncRNAs and miRNAs in thyroid cancer reveals SPTY2D1-AS1 as a new tumor suppressor.

Scientific reports·2022

Liquid biopsy offers promising biomarkers for diverse thyroid cancers. Advances in circulating tumor DNA, microRNAs, extracellular vesicles, and circulating tumor cells aid diagnosis and treatment monitoring.

Area of Science:

Oncology
Biomarker Discovery
Molecular Diagnostics

Background:

Thyroid cancer presents diverse subtypes, necessitating minimally invasive biomarkers.
Current diagnostic and monitoring methods require improvement for various thyroid cancer types.

Purpose of the Study:

To review recent advancements in liquid biopsy techniques for thyroid cancer.
To explore various analytes and technologies applicable to thyroid cancer liquid biopsies.
To provide a framework for selecting appropriate liquid biopsy analytes based on clinical needs.

Main Methods:

Review of circulating tumor DNA (ctDNA) technologies (qPCR/ddPCR, NGS) and strategies (tumor-informed/agnostic).
Analysis of circulating microRNAs (miRNAs) in bulk and extracellular vesicle (EV)-enriched samples.

Keywords:

CTCs ctDNA extracellular vesicles (EVs)liquid biopsy microRNAs thyroid cancers

More Related Videos

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Published on: September 16, 2022

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Published on: January 13, 2023

Related Experiment Videos

Last Updated: Jun 27, 2026

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Published on: September 16, 2022

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Published on: January 13, 2023

Examination of extracellular vesicles (EVs) and circulating tumor cells (CTCs) for diagnostic and prognostic applications.

Main Results:

ctDNA analysis faces challenges like low tumor fraction in differentiated thyroid cancer (DTC) but shows promise with methylation-based detection.
EV-miRNAs offer distinct advantages over bulk samples, with validated classifiers for metastatic disease and indeterminate nodules.
CTC research has evolved from enumeration to risk stratification and monitoring treatment response.

Conclusions:

An indications-first framework is proposed, matching analyte choice to clinical intent (diagnosis, risk stratification, treatment response, MRD).
Standardization and prospective validation are crucial for clinical adoption.
Integration of multi-analytes, cfDNA signals (epigenetic/fragmentomic), and advanced EV analytics will accelerate clinical use, especially in advanced thyroid cancer.